Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

No longer recruiting (closed or complete)Last updated: 21 December 2023

Mitotane TDM Study: This phase IV trial aims to identify ideal plasma levels of the drug Mitotane, by regular blood level monitoring and dose adjustmentMitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults

Trial purpose

Medical clipboardCancer treatment

Tumor type

Urinary System Cancers Genitourinary

Age

People0 - 100

Trial acronym

Mitotane TDM Study

Clinical summary

Summary

Mitotane is the only systemic treatment available for advanced adrenocortical cancer and is toxic, with variable pharmacokinetics (variable drug metabolism between patients). This study aims to achieve ideal plasma levels of the drug quickly by adjustment of the dose based on plasma level, and maintain the plasma level within the ideal range by regular blood level monitoring and dose adjustment. We also aim to study factors that contribute to variability between patients in their metabolism of the drug, and confirm a relationship between drug level and anticancer effect. As a consequence of this study we aim to provide a high quality therapeutic drug monitoring service for clinicians and patients with this disease in Australia.

Conditions

This trial is treating people with adrenocortical carcinoma

Eligibility

Inclusion

1. Adrenocortical carcinoma, any stage.
2. Treating physician is of the opinion that Mitotane therapy is indicated for the patient
3. Normal haematological parameters
4. Normal liver function
5. Adequate renal function
6. Eastern Co-operative Oncology Group (ECOG) performance status 0-2 .
7. No other significant medical illness.
8. Geographically accessible and physically capable of completing study investigations as required.
9. Informed consent for study investigations.

Exclusion

none

Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

Calvary Mater Newcastle

Scientific Title

Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information